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The prison-based N-ALIVE pilot trial had undertaken to notify the Research Ethics Committee and par-
ticipants if we had reason to believe that the N-ALIVE pilot trial would not proceed to the main trial. In
this paper, we describe how external data for the third year of before/after evaluation from Scotland's
National Naloxone Programme, a related public health policy, were anticipated by eliciting prior opinion
about the Scottish results in the month prior to their release as ofﬁcial statistics. We summarise how
deliberations by the N-ALIVE Trial Steering-Data Monitoring Committee (TS-DMC) on N-ALIVE's own
interim data, together with those on naloxone-on-release (NOR) from Scotland, led to the decision to
cease randomization in the N-ALIVE pilot trial and recommend to local Principal Investigators that NOR
be offered to already-randomized prisoners who had not yet been released.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Naloxone is an opioid antagonist used for emergency resusci-
tation following opioid overdose. Prisoners with a history of heroin
use by injection have a high risk of drug-related death (DRDs) in the
ﬁrst weeks after release from prison [1,2,3]. The N-ALIVE trial was
planned as a large prison-based randomized controlled trial (RCT)
to test the effectiveness of Naloxone-on-release (NOR) in the pre-
vention of fatal opiate overdoses soon after release (30% reduction
in the ﬁrst 4-weeks; 20% inweeks 5e12) [4]. The N-ALIVE pilot trial
(ISRCTN34044390) was a randomized feasibility study to test the
main trial's assumptions on recruitment of prisons and prisoners,
and also the logistics for ensuring that randomized participants
received their N-ALIVE pack on release [5]. See Meade et al. [6] forM. Bird).
r Inc. This is an open access articlehow delivery of the N-ALIVE protocol was achieved in 16 prisons in
England. See Parmar et al. [5] for the feasibility outcomes in the N-
ALIVE pilot trial. The N-ALIVE pilot trial had undertaken to notify
the Research Ethics Committee and participants if we had reason to
believe that the N-ALIVE pilot trial would not proceed to the N-
ALIVE main trial.
The start of Scotland's National Naloxone Policy (NNP) in
January 2011 [7], with funding for both NOR and community-based
take-home naloxone (THN), had pre-empted the N-ALIVE trial's
planned randomization in Scottish prisons. The primary outcome
for Scotland's science-led NNP-evaluation [8] was a 20%e30%
reduction in the proportion of opioid-related deaths (ORDs) with a
4-week antecedent of prison-release. As the proportion had been
10% in 2006e2010, Scotland's NNP had 80% power to discern
reduction to 7% in 2011e13, as upper target; or to 8% in 2011e15, as
lower target.
In this paper, we describe how external data for the third year ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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policy [7e10], were anticipated by eliciting prior opinion about the
Scottish results in the month prior to their release as ofﬁcial sta-
tistics [11,12]. We then describe how deliberations by N-ALIVE's
Trial Steering-Data Monitoring Committee (TS-DMC) on N-ALIVE's
own interim data, together with those on NOR from Scotland, led to
the decision to cease randomization in the N-ALIVE pilot trial and to
recommend to local Principal Investigators (PIs) that NOR be
offered to already-randomized prisoners who had not yet been
released [5].
To be ready to act promptly, we had elicited expert opinion
about the Scotland's forthcoming results [11] in order to focus on
the most probable scenarios for TS-DMC's decision-making. Un-
scheduled interim analysis was also undertaken of the N-ALIVE
pilot trial's own data from returned prisoner self-questionnaires,
speciﬁcally on the extent of NOR's administration intramuscularly
to the ex-prisoner for whom it had been prescribed versus to
another person.
We begin, therefore, with a brief history of formally eliciting
prior opinion to inform the design and monitoring of RCTs funded
by the UK's Medical Research Council (MRC); and some early ac-
counts of DMC deliberations. The back-story on the NALoxone
InVEstigation (N-ALIVE) follows, which puts our elicitation in
context, and sets the scene for deliberations and decisions by the N-
ALIVE's TS-DMC.
2. On elicitations for randomized trials funded by the Medical
Research Council and deliberations by Data Monitoring
Committees
The earliest example of formally eliciting prior opinion to inform
trial designwas “place your bets” about the mortality of surfactant-
treated very premature babies (aged 25e29 weeks) in a RCT funded
by MRC in the mid-1980s [13,14]. This “trial roulette” method was
again used in the design and early stopping of the MRC's neutron
therapy trial in pelvic cancer [15e18]: the minority prior belief on
the relative mortality of neutrons versus photons turned out to
have been consistent with trial's data. Following the early termi-
nation by the investigators of this neutron therapy trial, a decision
later ratiﬁed by a specially-convened post-hoc DMC, the MRC
required all of its RCTs to have a properly constituted DMC.
In 1994, Spiegelhalter, Freedman and Parmar [19] formalized
Bayesian approaches to RCTs. Their Bayesian design andmonitoring
of the CHART trials included a description of how prior elicitation of
clinicians' opinion could be used to form “enthusiastic” and
“sceptical” prior distributions [20]. Neither CHART trial was closed
to recruitment because, at each annual review, there was insufﬁ-
cient evidence to convert either the sceptics or the enthusiasts [21].
In 1999, on behalf of the Concorde, Alpha and Delta trials which
randomized patients with asymptomatic HIV infection, Armitage
(as DMC-chair) provided two insightful accounts of the DMC de-
liberations: the ﬁrst on interpreting early data and trends in sur-
rogate markers [22,23] and the second as clear-cut differences in
efﬁcacy gradually emerged [24]. See also Wittes [25]; Ellenberg,
Fleming and DeMets [26] for an early practical textbook; and the
injunction by Grant that DMCs must show strong resolve when
large unanticipated differences are inconsistent with existing evi-
dence from outside the RCT [27], as Goodman later endorsed [28].
By 2005, the DAMOCLES Study Group, like the MRC, had rec-
ommended that every RCT should have a DMC [29]; and proposed a
DMC charter to help them do their job well [30]. Of 20 questions
that DAMOCLES posed to 25 regulatory or funding organizations,
the two least likely to be answered were: on the training of DMC
members (2 responses) and on decision-making within DMCs (3
responses) [29]. For further examples of DMC decision-making, seeboth the DAMOCLES Study Group [29] itself (four examples) and
Pocock's editorial on when (not) to stop a clinical trial for beneﬁt
[31], in which he discussed the merit of the Haybittle-Peto
boundary which requires P < 0.001 as evidence to stop an RCT for
efﬁcacy.
Tharmanathan et al. [32] surveyed the use of interim data (with
or without the mention of DMCs) by RCTs published in eight major
journals: of 1772 RCTs published during 2000e2005, 470 (27%)
reported the use of a DMC and a further 116 (7%) some form of
interim analysis without explicit mention of a DMC; see also Sydes
et al. [33] (for the DAMOCLES Study Group) who had contrasted
DMC-mentions in 1990 versus 2000.
3. Back-story on the N-ALIVE pilot trial and Scotland's
National Naloxone Policy
In late summer 2008, the MRC funded the pilot phase (that is:
ﬁrst 10% of randomizations) of the N-ALIVE Trial [4,5,6] which was
to run in two prison jurisdictions (Scotland; England&Wales). Pro-
rata in each jurisdiction, 2800 consented eligible prisoners with a
history of heroin-injection were to be randomized during incar-
ceration to receive their assigned N-ALIVE pack on-release. The trial
was double-blind only until participants opened their assigned N-
ALIVE pack immediately after release.
The randomization ratio was 1:1. The N-ALIVE control packs
contained no syringe and no naloxone. The naloxone packs con-
tained a syringe of naloxone for “rescue” injection in the event that
the participant overdosed on opioids [1e3]. The syringe contained
2 mg of naloxone hydrochloride in 2 ml of solution, for once-only
intramuscular (IM) injection in the event of overdose. During in-
formation and consent sessions while incarcerated, all N-ALIVE
participants were advised on how to administer 0.8mg of naloxone.
The N-ALIVE pilot trial was designed to investigate the feasi-
bility of randomized provision of NOR to eligible prisoners. The
deﬁnitive N-ALIVE Trial would determine if NOR reduced partici-
pants' drug-related deaths (DRDs) by 30% in the ﬁrst 4-weeks after
release and by 20% in the subsequent 8 weeks [4,5,6]. Per 2800
releases in the control group, we expected 14 DRDs in the ﬁrst 4-
weeks and 3.5 DRDs in the subsequent 8 weeks [4,5].
As high risk of overdose death soon after prison-release applies
per-release, re-randomization was permitted provided that at least
six months had elapsed since the participant's previous N-ALIVE
release-date.
3.1. Contamination between randomized groups?
In designing the N-ALIVE pilot trial, we had anticipated
contamination between randomized groups of up to 20% because
participants who had been randomized to NOR might administer
their naloxone alternatively to an opioid-dependent peer who had
overdosed, some of whom - unknown to us - might have been
randomized to N-ALIVE's control group.
Speciﬁcally, if ex-prisoners' 8 times higher DRD-risk in the ﬁrst
fortnight after release [1] was on account of an 8 times higher
overdose-risk then, assuming that one of (say) three co-present
injectors overdoses, there is an 80% chance that the person who
overdosed was the recently-released ex-prisoner to whom
naloxone (if also present) will therefore be administered.
However, if injectors' chance of opioid overdose is the same
regardless of recent prison-release, so that recently-released ex-
prisoners' DRD-risk is due to an 8 times higher fatality-rate per
opioid overdose, then each of the injector-triad above has the same
chance of opioid-overdose. In this scenario, there is potentially a
two-thirds chance that the ex-prisoner's NOR is administered to
another person so that contamination between N-ALIVE's
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especially so if, in addition, there is assortative mixing of recently-
released prisoners.
Contamination was assessed in the N-ALIVE pilot trial by asking
participants who were returned to prison to complete a returned
prisoner self-questionnaire (RPSQ). The questionnaire asked par-
ticipants about overdose soon after release, and whether naloxone
was administered before the arrival of an ambulance; and also
about their presence when someone else overdosed, and whether
naloxone was administered before the arrival of an ambulance [5].
3.2. Pre-emption of N-ALIVE's randomization by National Naloxone
Policies (NNPs) in Scotland and Wales
The decision in spring 2010 by Scotland's Minister for Safety and
Communities to introduce Scotland's NNP from January 2011 pre-
empted N-ALIVE's randomization in Scotland [7,8].
Scotland became the ﬁrst country in the world to have a funded
public health policy of NOR for at-risk prisoners and THN for
community-based opioid users. Wales [34,35] followed Scotland's
lead later in 2011, so that the N-ALIVE pilot trial could randomize in
English prisons only. In May 2012 at Nottingham Prison, the N-
ALIVE pilot trial randomized its ﬁrst participants [6]. By the end of
October 2014, 1570 participants had been randomized by 16
participating prisons in England.
3.3. Before/after evaluation of Scotland's National Naloxone Policy
Scottish ministers made provision for 33,000 naloxone-kits (at
£11 per kit) to be issued during 2011e2013. In the event, the min-
isterial target took ﬁve years to be achieved and the cost per kit
increased to £18 [9].
Based on Scotland's 1970 ORDs in 2006e2010 [36] versus
around 1200 expected in 2011e2013 [8], the before/after evalua-
tion of Scotland's NNPwas designed to have 80% power to discern a
30% reduction in the proportion of prison-release ORDs (down from
10% to 7%) and a 20% reduction in the proportion of ORDs with a 4-
week antecedent of prison-release and/or hospital-discharge
(down from 20% to 16%).
Scotland's number of ORDswas not an effectiveness outcome for
2011e2013 because ORDs in Scotland (also in England and Wales
[9]) had been on an age-related rising trajectory during the ﬁrst
decade of the 21st century [8,12]. Moreover, ORDs were susceptible
to sharp changes in the illicit heroin market.
4. Anticipatory elicitation
On behalf of Scotland's National Naloxone Advisory Group, the
Information Services Division (ISD) in Scotland undertook the look-
backs from Scotland's ORDs to establish their 4-week antecedent of
i) prison-release and ii) prison-release and/or hospital-discharge.
Findings were reported as ofﬁcial statistics [36]. Prior to 28
October 2014 [11], the baseline proportion of Scotland's ORDs in
2006e10 with a 4-week antecedent of prison-release and/or
hospital-discharge had not been published; but was expected to be
around 20%.
Table 1 shows the published information at the end of August
2014 [12,36] on NNP's primary and secondary outcomes for the
baseline period of 2006e2010; and for 2011e2013. With ministe-
rial endorsement, Scotland had set regional targets for the
community-issue of THN in 2013/14 so that Scotland's issued
naloxone-kits in 2013 would almost surely exceed those in 2012
(and did [11]).
Please see Supplementary Material for the invitation and
elicitation-brieﬁng that was issued to three cadres of individualsfrom whom we wished to elicit prior opinion: a) some 30
statistician-members of MRC Biostatistics Unit who attended a
Workshop on Evidence Synthesis for Health in September 2014, b)
four selected members of Scotland's National Naloxone Advisory
Group and c) ﬁve members of the N-ALIVE pilot Trial team (its
principal investigators; AMM; and trial-statistician). Even for bio-
statisticians, elicitation of expert opinion on a joint outcome was
tricky as their low response-rate may indicate. The required joint
outcome was: i) Scotland's number of ORDs in 2013 with a 4-week
antecedent of prison-release (X3 in Table 2) and ii) Scotland's
number of ORDs in 2011e2013 with a 4-week antecedent of
hospital-discharge but not prison-release (HD in Table 2). Re-
sponses were received as follows: a) 11, b) 4 and c) 4. One of the 19
respondents offered an opinion only on i).
Table 2 shows the summed responses from the above three
elicitation-sources. The attention of the N-ALIVE pilot trial's TS-
DMC was focused on the elicitation's three (out of nine) top-
belief cells which together accounted for 50% of assessors' prior
belief. As we learned subsequently on 28 October 2014, the actual
outcomes were: i) 18 ORDs in 2013 with a 4-week antecedent of
prison-release and ii) 181 ORDs in 2011e2013 with a 4-week
antecedent of prison-release and/or hospital-discharge so that the
number of ORDs in 2011e13 with a 4-week antecedent of hospital-
discharge but not prison-release equalled 181-76, or 105 [9,11].
5. Deliberations and decisions by N-ALIVE's Trial Steering-
Data Monitoring Committee
In this section, we sketch the rationale for and main business of
the N-ALIVE pilot trial's TS-DMC prior to October 2014. We then
detail the TS-DMC's deliberations in October and November 2014.
The N-ALIVE pilot trial's emerging data on ORDs (now maxi-
mally for 2800 participants; versus 56,000 required to demonstrate
NOR's a priori plausible effectiveness [4,5,8]) were highly unlikely
to achieve a sufﬁcient signal-noise ratio on effectiveness and so a
joint TS-DMC had been appointed (which DA chaired). Membership
included N-ALIVE's three co-principal investigators (JS, MKBP,
SMB). The TS-DMC's independent chair and membership would,
we hoped, form the nucleus of the main trial's DMC.
Prior to October 2014, the main business of the N-ALIVE pilot
trial's TS-DMC had been to support the recruitment of a sufﬁcient
number of prisons in England; to deliberate on reasons for fewer
prisoners with a history of heroin injection being identiﬁed by our
prison-based N-ALIVE workers than anticipated by the number of
prisoners engaged in drug treatment in 2005/06 [6]; and to engage
governors in promoting their security staff's acceptance that our
assigned N-ALIVE packs should be held with the prisoner's valu-
ables [5,6].
Our TS-DMC members had not expected to confront critical
ethical decisions on whether to cease randomization in the N-
ALIVE pilot trial. However, from the outset, their responsibilities did
include the review of external evidence and recommending
whether the pilot trial should continue to the N-ALIVE main trial.
The TS-DMC did not take formal action on NNP's interim data for
2011 þ 2012 on prison-release ORDs, see Table 1, which had
decreased signiﬁcantly (p < 0.01) from 9.8% (193/1970) in
2006e2010 to 7.0% (58/829) in 2011 þ 2012 as the wide conﬁdence
interval and NNP's before/after design warranted only a watching
brief. Moreover, by the end of October 2013, the N-ALIVE pilot trial
had received fewer than 70 of its own RPSQs.
In October 2014, however, TS-DMC members were faced by
external data which required tense and careful deliberation. Prior
elicitation of expert opinion had served to sensitize members to the
sorts of decision that might have to be made. The elicitation results
were considered by N-ALIVE's TS-DMC at its meeting on 20 October
Table 1
Published information by end August 2014 [9,10] on the primary and secondary outcomes for Scotland's National Naloxone Policy (NNP): baseline period of 2006e2010 versus
2011e2013. Before/after evaluation of Scotland's National Naloxone Policy& set-up for ELICITATION of unknown counts X3 and HDwhere X3 is the number of Scotland's
383 ORDs in 2013 with 4-week antecedent of prison-release andHD is the number of Scotland's 1212 ORDs in 2011e213 with 4-week antecedent of hospital-discharge but not
prison-release.
PERIOD Naloxone-kits 
issued in 
Scotland 
(including by 
prisons)
Percentage of Scotland's opioid-related deaths (ORDs) 
with 4-week antecedent of:
Prison-release
PRIMARY 
OUTCOME
Prison-release and/or hospital-
discharge
SECONDARY OUTCOME
2006-10: Baseline 193/1970: 9.8% NK /1970: ~ 20%
2011 2 487  (   570) 36/  430: 8.4% NK / 430
2012 3 878  (   725) 22/  399: 5.5% NK /  399
2013 NK     (  NK) X3/  383: NK /  383
2011-13: NNP's first three 
years
{58 + X3}/1212 {58 + X3 + HD}/1212
NK = not known
Table 2
Summation of responses across three elicitation-sources.
Elicited peer opinion on both X3 and HD, where:
X3 /383 ORDs in 2013 with a 4-week antecedent of prison-release in 2013 
&
{58 + X3 + HD}/1212 ORDs in 2011-2013 with a 4-week antecedent of prison-release 
and/or hospital-discharge.
PRIOR 
BELIEFS:
1800 BETS
Placed on 
HD; 
1900 BETS
Placed on 
X3
HD <75 75-79 80–
84
85-89 90-94 95–
104
>104
Marginal
% 
Distributions
448/1800 769/1800 583/1800
25% 43% 32%
<22
873/1900
46%
11%
201/1800
17%
301/1800
15%
271/1800
22-28
683/1900
36%
8%
144/1800
18%
323/1800
12%
216/1800
>28
344/1900
18%
6%
103/1800
8%
145/1800
5%
96/1800
Disclosed as official statistics on 28 October 2014, the realizations were:  X3 = 18
and HD = 105.
S.M. Bird et al. / Contemporary Clinical Trials Communications 5 (2017) 100e106 1032014, eight days ahead of ISD's ofﬁcial statistics release [11]. The TS-
DMC was also made aware of commissioners' plans for prisons in
the NorthWest region of England to issue NOR to eligible prisoners;
and that, if funding for the N-ALIVE pilot trial was not to be
extended beyond March 2015, randomizations would have to cease
by the end of December 2014 to allow time for 12-weeks’ follow-up
and an orderly closure of the N-ALIVE sites.
The TS-DMC minutes recorded that, following the release of the
third year of results on Scotland's NNP [11] on 28 October 2014, a
teleconference would be organized to decide the course of action
for N-ALIVE. In practice, the TS-DMC chair asked that the TS-DMC's
initial deliberations be conducted by email as an analyticalsummary of Scotland's 3-year results for 2011e2013 had to be
prepared. Also, in view of the late registration of coroner-referred
deaths in England and Wales, information on ORDs in Wales and
England by death-year, rather than by the year of death-
registration, were needed to set Scotland's ORDs in context
[9,37,38].
As Scotland's 3-year results coincided with one of the three cells
in Table 2 wherein lay 50% of the prior belief, the elicitation exercise
had served mainly as reassurance that prior beliefs and realization
were not at odds. There was no added scepticism [19e21] to be
weighed in the balance.
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Key considerations were:
a) N-ALIVE pilot trial's undertaking to participants and to the
Research Ethics Committee that they would be notiﬁed
immediately if the principal investigators had reason to
believe that the N-ALIVE main trial could not go ahead as
planned;
b) N-ALIVE pilot trial's own data from RPSQs, together with
Scotland's information from re-supplies, showed that NOR
was administered to another: self in the ratio 15:5 and 21:12
(that is: 36:17 or 2:1), giving an upper 99% conﬁdence limit
of 50% for NOR's administration to the recently-released
prisoner as assigned;
c) Effect-size for Scotland's primary outcome of prison-release
ORDs (p < 0.001) [31] was consistent with the a priori tar-
gets adopted by the N-ALIVE main trial but Scotland's
recently-released prisoners potentially beneﬁtted from
community-issued THN as well as from NOR;
d) Association is not causation, and so Scotland's before/after
comparison needed to be appraised in the light of Hill's
criteria on causality [9,39];
e) Scotland's NNP outcomes were published annually as ofﬁcial
statistics but a formally peer-reviewed report on NNP's
outcomes in 2011e13 versus 2006e10 [9] was lacking;
f) As Europe's largest prison-based randomized controlled trial
(RCT) [6], if the N-ALIVE pilot trial ceased randomizing,
damage could be done internationally to the case for prison-
based RCTs;
g) As the N-ALIVE trial's participants were held in prison cus-
tody, the highest ethical standards would be maintained by
TS-DMC on their behalf;
h) The likely consequence in England - if the N-ALIVE pilot trial
ceased randomizing eligible prisoners in the ratio 1:1 be-
tween NOR and control - was that no eligible prisoner in
England would receive NOR rather than, as now, half of those
who participated from N-ALIVE prisons;
i) Hence, continued prison-based randomization would be
ethical on the basis that NOR was a rationed or restricted
resource;
j) Upon release, N-ALIVE's participants are as free as any other
citizen is to obtain THN by prescription, for example by
requesting it from their general practitioner;
k) Finally, N-ALIVE's principal investigators were scientiﬁcally-
bound to consider and promote randomized alternatives,
such as randomized step-wedge designs, to ensure that as
robust evidence as possible could be got [40,41] from the
instigation of regional NNPs in England.
Considerations c) to e) were addressed by SMB's drafting for
consideration by TS-DMC of a 3-year report on Scotland's NNP
outcomes. This report, which included the application of Hill's
criteria on causality [39], formed the basis of a co-authored, peer-
reviewed subsequent publication in Addiction [9]. Considerations f)
to k) were addressed by JS's drafting of an ethical and wider sci-
entiﬁc counter-case for continued randomization.
Considerations f) and g) were balanced by considerations i) and
j). The fairness of continued randomizationwhen a resource such as
NOR is scarce or restricted is a strong argument, both scientiﬁcally
and ethically. TS-DMC's duty is, however, primarily to participants
in the trial which the TS-DMC was convened to oversee [29].
Considerations h) and k) were met by the N-ALIVE co-principal
investigators' letter to England's Chief Medical Ofﬁcer to appraise
her of the Scottish data, the decisions to be taken in respect of theN-ALIVE pilot trial and the likely cost-effectiveness of a NNP in
England which should aim to issue 9000 to 20,000 naloxone-kits
per annum [8], including NOR for eligible prisoners as in Scotland
[9,42] and Wales [35].
5.2. Decisions: 18 November to 1 December 2014
According to its charter [6], the N-ALIVE pilot trial's TS-DMCwas
quorate at its meeting on 18 November 2014 because two inde-
pendent members (DA and SW) were present in addition to the
three principal investigators. But, because the TS-DMC was
considering a major action, the TS-DMC chair needed to commu-
nicate with the absent members (JP and JRR) as soon after the
meeting as possible to check if they were in agreement. If not, a
further teleconference should be arranged with the full TS-DMC.
Considerations a) and b) were deciding factors: we estimated
that at least half the administrations of NOR in the N-ALIVE main
trial would be to some-one other than the ex-prisoner for whom
NOR had been prescribed. Even without NOR-administered
contamination of the N-ALIVE control group, the number to be
randomized in the N-ALIVE main trial would be excessive (over
150,000). Worse, substantial contamination, in excess of 20%, could
not be ruled out and so the main trial could not go ahead.
The N-ALIVE pilot trial's TS-DMC decided, on the basis of a) and
b), that randomization should cease in the N-ALIVE pilot trial on 8
December 2014. Because of the strength of the evidence from
Scotland's NNP (since peer-reviewed [9]) and the WHO Guidelines
published on 5th November 2014 [40,41], the TS-DMC recom-
mended to local PIs that, once randomization ceased, all random-
ized participants who remained in prison should be offered NOR (ie
thosewho had been allocated to control as well as those assigned to
NOR). Submission to the Research Ethics Committee was made on
21 November 2014, which notiﬁed its approval on 1 December 2014
of the TS-DMC's recommendations and N-ALIVE's updated infor-
mation for participants on the basis for its decisions (see http://
www.ctu.mrc.ac.uk/our_research/research_areas/other_
conditions/studies/n_alive/). The TS-DMC's recommendations were
also endorsed by N-ALIVE's prison-based investigators who put
them into force.
6. Concluding remarks
The elicitation of expert opinion on the Scottish NNP's likely
outcomes during 2011e13, when they would be available anyway
in less than twoweeks, set the scene for the TS-DMC's deliberations
but was not otherwise inﬂuential, because prior beliefs and reali-
zation were consistent; not contradictory.
Time for reﬂection and appraisal of causality were necessary for
TS-DMC's decisions to have been reached unanimously on what to
do in respect of serving prisoners who had been randomized to the
control group.
The critical decision e that an individually-randomized
controlled trial of naloxone-on-release had been shown to be the
wrong design because at most half the administrations of NOR
were to the ex-prisoner as assigned e was more easily made. The
elicitation of expert opinion had no bearing on this decision, for
which the dominant considerationwas consistency of another: self
ratio between N-ALIVE's RPSQs and Scotland's information from
NOR re-supplies.
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